Opportunity
SAM #75N98026Q01182IMAGINEOPTIC
Procurement of TFI Add-on Module for rtx1 Adaptive Optics Retinal Camera
Buyer
NIH Office of Logistics and Acquisition Operations
Posted
September 09, 2026
Respond By
September 18, 2026
Identifier
75N98026Q01182IMAGINEOPTIC
NAICS
423490, 339112, 423460, 423450
The National Institutes of Health (NIH) Office of the Director, Office of Acquisitions, is seeking to procure a specialized add-on module for advanced retinal imaging. - Government Buyer: - National Institutes of Health (NIH) - Office of the Director - Office of Acquisitions - Products Requested: - Transscleral Flood Illumination (TFI) add-on module for the rtx1 Adaptive Optics Retinal Camera - Quantity: 1 - Extends imaging capability for microscopic retinal analysis, enabling visualization of small retinal structures beyond photoreceptors - Intended for clinical trials, disease monitoring, and research applications - Shipping (Quantity: 1) - Tariff Charge (Quantity: 1) - OEMs and Vendors: - The solicitation references the rtx1 Adaptive Optics Retinal Camera and TFI module, commonly manufactured by Imagine Optic (not explicitly named in the documents) - Unique Requirements: - The TFI module must be compatible with the rtx1 Adaptive Optics Retinal Camera - Technology is intended for high-resolution retinal imaging at the cellular level - Supports clinical and research use, including monitoring ocular diseases - No specific part numbers provided - Open competition; not set aside for small businesses
Description
1: Transscleral Flood Illumination (TFI) add-on module for the rtx1 Adaptive Optics Retinal Camera 2: The Transscleral flood illumination module for the rtx1 extends the imaging capability of the rtx1 Adaptive Optics camera. It provides a tool for investigating retinal anatomy, pathology and therapy at the microscopic scale beyond photoreceptors. This technology enables visualization of small retinal structures that are usually invisible in adaptive optics images. This technology could prove helpful in clinical trials and demonstrate capability in monitoring the progression of various ocular diseases at a cellular level before significant damage sets in